Special topic: Recent developments in psychiatric ratingDepressive symptoms in acute schizophrenia
References (10)
- et al.
Development of a schizophrenia scale sensitive to change
Neuropharmacology
(1978) - et al.
The Comprehensive Psychopathological Rating Scale
Acta Psychiat. Scand. Suppl.
(1978) - et al.
Diagnostic criteria for use in psychiatric research
Arch. Gen. Psychiat.
(1972) Development of a rating scale for primary depressive illness
Brit. J. Soc. Clin. Psychol.
(1967)- et al.
A new depression scale designed to be sensitive to change
Brit. J. Psychiat.
(1979)
Cited by (50)
A case report of clozapine-treatment-resistant schizophrenia successfully managed with brexpiprazole combination therapy
2022, Asian Journal of PsychiatryTobacco smoking and nicotine dependence in first episode and established psychosis
2019, Asian Journal of PsychiatryL-Methylfolate For Bipolar I depressive episodes: An open trial proof-of-concept registry
2017, Journal of Affective DisordersCitation Excerpt :Clinician and patient-rated study measures were collected at every visit. Depressive symptoms were assessed with the Montgomery Asberg Depression Rating Scale (MADRS) (Montgomery, 1979) and manic symptoms with the Young Mania Rating Scale (YMRS) (Young et al., 1978). Clinical Global Impressions - Bipolar Severity (CGI-BP-S) (Spearing et al., 1997) was administered to integrate symptoms and burden.
Asenapine: Efficacy and safety of 5 and 10 mg bid in a 3-week, randomized, double-blind, placebo-controlled trial in adults with a manic or mixed episode associated with bipolar i disorder
2016, Journal of Affective DisordersCitation Excerpt :CGI-BP-S is a single-item clinician-rated scale with a possible score ranging from 1 to 7, with higher scores indicative of more severe illness (Guy, 1976a; Spearing et al., 1997). The Positive and Negative Symptom Scale (PANSS) was administered on days 7, 14, and 21, and the Montgomery–Åsberg Depression Rating Scale (MADRS) was administered on days 7 and 21 (Kay et al., 1987; Montgomery, 1979). PANSS is a 30-item clinician-rated instrument; decreases from baseline in PANSS scores are indicative of an improvement in symptoms.